SBIR/STTR Research Award
Clinical Validation of the Multiple Biopsy Device, a Novel Endoscopic Biopsy Technology
Award amount
$206,274Program and phase
SBIR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ENDOSCOPY ASSIST DEVICES LLC
- Proposal award date
- 2018-06-07
- Contract end date
- 2019-05-31
- UEI
- QLTCVSA4S5E1
- Solicitation number
- PA17-302
- Topic code
- 102
Research abstract
Project Abstract
The objective of this proposal is to complete clinical validation of the Multiple Biopsy DeviceMBDan
endoscopic device that will revolutionize endoscopic practice by improving the efficiency of endoscopic biopsyeliminating the loss of critical specimensand improving the safety of endoscopic biopsy for both practitioners
and patientsOvermillion endoscopic procedures will require endoscopic biopsy in the yearand the
number of diagnostic endoscopic procedures is expected to grow byper year over the next decadeCurrently marketed biopsy devices require a separate pass of the device everybitesClinical protocols for
endoscopic biopsy require multiple passes to satisfy the total number of specimens needed to achieve diagnostic
certaintyadding significant time pressures to already overburdened endoscopistsWe have developed a device
that will allow the acquisition of an unlimited number of biopsies from one pass of the biopsy deviceThe MBD
operates by mechanically harvesting a mucosal specimen taken for histologic analysisthen transporting the
specimen to a collection device located outside of the endoscopeBiopsies from different lesions or locations
can be segregated in separate sample cups to avoid confusion about their site of originationFurthermorethe
MBD collection container will greatly speed up transfer of specimens from the collection device to formalin cupswhile eliminating the risk of impalement by the central spike during the retrieval of samples from the cups of the
biopsy forcepsThe following specific aims will complete MBD validation in preparation for regulatory submissionSASpecific AimiDesign and implement a Design Trace MatrixDTMRisk Management Plan and
associated protocols for manufacturing and testing clinical grade MBDsiiConstruct an adequate number of
medical devices using contract manufacturers for supplying components for final assembly and packaging by
EADincluding a sterilization safety study
SAConduct a phase I Feasibility Study to support a future pivotal trialThis will consist of a RBDPB crossover trialas detailed in the Research Strategy sectionnSuccessful completion of this SBIR funded development program will support the commercialization of a
paradigm shifting diagnostic device that will dramatically improve the process of endoscopic biopsywhile
maximizing patient and ancillary staff safety Project Narrative
Endoscopy Assist DevicesLLCwill clinically validate the Multiple Biopsy DeviceMBDa novel
technology that will enable endoscopists to take and retrieve an unlimited quantity of biopsy specimens
with one pass of the biopsy deviceThis feature will greatly expedite acquisition times when multiple
samples are required for diagnosiswhile eliminating lost specimens and the risk of lacerations from
the spike found on current biopsy devicesIn the present applicationwe propose to clinically validate
the MBD in a first in human clinical trialThe work completed during the period of this grant will position
the MBD for subsequent commercialization efforts and licensing opportunities
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- MiREA, a mHealth intervention to Reduce Health Disparities by Improving Equitable Access to Mandated College Students with Problematic Alcohol and Marijuana Use
- Modex, a cloud-based, centralized health economic model marketplace to reduce costs and enhance equity in cancer
- Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas
- Allogeneic cell and gene therapy for neuroendocrine tumors
- Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer